These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 22947250)

  • 1. Advances with vaccination against Neisseria meningitidis.
    Borrow R
    Trop Med Int Health; 2012 Dec; 17(12):1478-91. PubMed ID: 22947250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New frontiers in meningococcal vaccines.
    Anderson AS; Jansen KU; Eiden J
    Expert Rev Vaccines; 2011 May; 10(5):617-34. PubMed ID: 21604983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.
    Su EL; Snape MD
    Expert Rev Vaccines; 2011 May; 10(5):575-88. PubMed ID: 21604979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine.
    Bai X; Borrow R
    Expert Rev Vaccines; 2010 Oct; 9(10):1203-17. PubMed ID: 20923270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent developments in vaccines to prevent meningococcal serogroup B infections.
    Vermont CL; van den Dobbelsteen GP; de Groot R
    Curr Opin Mol Ther; 2003 Feb; 5(1):33-8. PubMed ID: 12669468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serogroup A meningococcal conjugate vaccines in Africa.
    Kristiansen PA; Jørgensen HJ; Caugant DA
    Expert Rev Vaccines; 2015; 14(11):1441-58. PubMed ID: 26358167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quest for a broad-range vaccine against Neisseria meningitidis serogroup B: implications of genetic variations of the surface-exposed proteins.
    de Filippis I
    J Med Microbiol; 2009 Sep; 58(Pt 9):1127-1132. PubMed ID: 19528146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neisseria meningitidis B vaccines.
    Panatto D; Amicizia D; Lai PL; Gasparini R
    Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.
    Nissen MD; Marshall HS; Richmond PC; Jiang Q; Harris SL; Jones TR; Jansen KU; Perez JL
    Pediatr Infect Dis J; 2013 Apr; 32(4):364-71. PubMed ID: 23114369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal disease: a review on available vaccines and vaccines in development.
    Bröker M; Fantoni S
    Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
    Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
    Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate.
    Delgado M; Yero D; Niebla O; González S; Climent Y; Pérez Y; Cobas K; Caballero E; García D; Pajón R
    Vaccine; 2007 Dec; 25(50):8420-31. PubMed ID: 17996338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling serogroup B invasive meningococcal disease: the Canadian perspective.
    Bettinger JA; Deeks SL; Halperin SA; Tsang R; Scheifele DW
    Expert Rev Vaccines; 2013 May; 12(5):505-17. PubMed ID: 23659299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
    Andrews SM; Pollard AJ
    Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines.
    Villena R; Safadi MAP; Valenzuela MT; Torres JP; Finn A; O'Ryan M
    Hum Vaccin Immunother; 2018 May; 14(5):1042-1057. PubMed ID: 29667483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.